<DOC>
	<DOCNO>NCT01503983</DOCNO>
	<brief_summary>The objective study assess efficacy safety Trastuzumab combination Capecitabine+Oxaliplatin first-line treatment patient advance metastatic gastric cancer gastro-esophageal junction , ( HER2 ) -positive .</brief_summary>
	<brief_title>Efficacy Safety Trastuzumab , Capecitabine Oxaliplatine Treatment Gastric Cancer Metastatic ( HER2 ) Positive</brief_title>
	<detailed_description>Gastric cancer worldwide second tumor incidence ( 10 % ) . There significant geographical difference Spain incidence 15 cases/100,000 per year . Although incidence mortality gastric cancer ( GC ) experience mark reduction past 40 year , disease remain leading cause cancer-related mortality , account 870,000 death worldwide year 2000 . Gastric cancer high mortality rate usually diagnose advanced stage many case high relapse rate . Advanced gastric cancer case consider diagnosed unresectable disease , either locally advanced disease ( 30 % case diagnosis ) , metastatic disease ( another 30 % ) patient relapse ( 60 % resect ) . Thus , overall around 84 % patient gastric cancer advance disease . The curative treatment far surgery . Thanks early detection implementation appropriate surgical technique , survival improve country Japan Korea , rate 5-year survival 47 % Over year , large number study single agent chemotherapy show gastric cancer relatively sensitive chemotherapy . Based observation , trend investigation combination chemotherapy agent . Based result FDA EMEA approve capecitabine treatment advance gastric cancer combine platinum .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients able grant write informed consent oral consent Age ≥18 year old Patients diagnose metastatic gastric gastroesophageal junction adenocarcinoma ( HER2positive ) , unresectable histologically confirm Measurable disease , follow new RECIST criterion , HER2 positive tumor ( primary metastatic ) overexpression HER2 determinated IHQ +++ ( IHQ3+ ) IHQ ++ confirm FISH/SISH positive ( IHQ2+/FISH+ ) ECOG ≤ 2 Patients childbearing potential ( &lt; 12 month last menstruation ) , use effective mean contraception Life expectancy 3 month Adequate renal function : calculated creatinine clearance &gt; 50 mL/min Adequate liver function : AST ALT ≤2.5 x LSN ( 5 x LSN liver metastasis ) , bilirubin 1,5 x LSN . alkaline phosphatase &lt; 2,5 x LSN ( ≤ 5 x LSN liver metastasis &lt; 10 x LSN bone metastasis Adequate haematological function : Hb ≥9 g/dl , neutrophils ≥ 1,5 x 109 /l platelet 100 x 109 /l . Normal Left Ventricle Fraction Ejection , LVEF &gt; 50 % Every patient treat follow / study site Prior chemotherapy treatment advanced/metastatic disease Lack physical integrity upper gastrointestinal tract malabsorption Patients active gastrointestinal bleeding Prior chemotherapeutic treatment advance / metastatic disease Toxicity result prior therapy ( except alopecia ) . , example . Neurology toxicity grade ≥2NCICTCAE Patients receive radiotherapy within 4 week prior study treatment . Major surgical procedure within 4 week prior treatment without total surgical recovery . Past current history malignancy ( within last 52 year prior treatment start ) , patient curatively treat basal cell carcinoma skin situ carcinoma cervix eligible Active clinically significant cardiovascular disease , History current clinical evidence brain metastasis Patients undergoing transplantation allogenic require immunosuppressive treatment Moderate severe renal failure , creatinine clearance &lt; 50 mL/min , calculate CockcroftGault Adequate liver function : bilirubin ≤1.5 x UL , GOT ( ASAT ) / GPT ( ALAT ) ≤2,5 LSN . Liver metastasis ≤ 5 x LSN , FA ≤ de 2,5 feces el LSN . Adequate haematology function : neutrophil ≥ 1,5 x 109 /l platelet 100 x 109 /l Treatment sorivudine analogous brivudine . Dihydropyrimidine proven dehydrogenase deficiency ( DPD ) . Patients receive drug , agent investigational procedure , participate another research study within 30 day prior initiation treatment study medication . Hypersensitivity study drug Evidence disease , metabolic dysfunction , physical examination find laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put patient high risk treatmentrelated complication Patients receive chronic corticosteroid therapy high dose ( allow use inhaled steroid cycle short treatment oral steroid prevention emesis stimulate appetite ) Pregnancy lactation Patients childbearing potential willing use effective mean contraception . History psychiatric disorder investigator consider clinically significant , cause patient give inform consent interfere compliance study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Gastric Cancer Metastasis</keyword>
	<keyword>HER2-positive</keyword>
</DOC>